Blog & Analysis #phispers #pharmaflow

This week, Phispers brings you news about the FDA classifying three plants of Indian drug major Aurobindo Pharma and an Alkem Laboratories plant in the US as Official Action Indicated (OAI). Gilead’s new CEO Daniel O’Day defended&n...

This week, Phispers is loaded with news from the US. First, a coalition of 44 states sued Teva and 20 other generic companies for price fixing.  Second, a new book titled ‘Bottle of Lies’, by investigative journalist Katherine Eba...

This week, Phispers brings you news about John Kapoor, the founder of Insys who was found guilty of engaging in a bribery scheme to get doctors to prescribe a highly potent and addictive opioid. FDA granted approval to Pfizer’s rare and fatal...

This week, there is news on EMA telling companies using certain reagents to make diabetes drug — pioglitazone — to check their processes and rule out the presence of a nitrosamine impurity.  Bayer faced shareholder revolt for p...

This week Phispers has news on regulatory action, a new CEO appointment, lobbying, data theft and layoffs. Another plant of Indian drugmaker Lupin received an OAI letter from the USFDA. After companies like GSK, Eli Lilly and Genentech, data...

The drug pricing debate continued to dominate news headlines in 2018, and many companies were in the news for lowering drug prices to make treatments more affordable. Despite that, most major pharmaceutical companies saw their sales grow in 2018.&n...

This week, Phispers brings you an update on the US$ 74 billion BMS-Celgene mega-merger, which was facing investor opposition. The shareholders of BMS have approved the takeover of Celgene. French drugmaker Sanofi announced an innovative model to ma...

This week, Phispers has good news for patients on sartan drugs. For the first time since nitrosamine impurities were discovered last year, the USFDA released a list of BP drugs that are safe for patient use. The EU launched a WTO case against Tur...

This week, Phispers brings you news about AstraZeneca’s US$ 6.9 billion deal with Japanese drug major Daiichi Sankyo, wherein the two will jointly develop a promising cancer therapy currently in phase III trials. Novartis acquired a portfolio...

This week, PharmaCompass reviews the recently released data of the Medicare Part D Prescription Drug Program in the United States for calendar year 2017. The US market is the world’s largest and most important pharmaceutical market, accountin...